由于市场挑战,Lifecore生物医学在2025年第四季度损失了600万美元,但预计2026年的收入将达到1200万美元至1250万美元. Lifecore Biomedical lost $6M in Q4 2025 amid market challenges but expects 2026 revenue of $120M–$125M.

Lifecore Biomedical 报告 2025 年第四季度净亏损 600 万美元，每股亏损 0.16 美元，收入为 3570 万美元。 Lifecore Biomedical reported a net loss of $6 million, or $0.16 per share, for its fourth quarter of 2025, with $35.7 million in revenue. 2025年全年结果显示,1.289亿美元的收入损失3 870万美元,即每股1.27美元。 Full-year 2025 results showed a loss of $38.7 million, or $1.27 per share, on $128.9 million in revenue. 该公司预计2026年的收入将在1.2亿至1.25亿美元之间。 The company expects 2026 revenue between $120 million and $125 million. 它列举了当前的市场挑战,包括供应链的转变以及影响产品推出的融资延误。 It cited ongoing market challenges, including supply chain shifts and funding delays affecting product launches. 尽管出现净亏损,但该公司注意到利润率提高,业务开支减少,现金正流动,不包括优先股本付款。 Despite a net loss, the company noted improved margins, reduced operating expenses, and positive operating cash flow, excluding a preferred stock payment. 它还强调了欧洲和亚洲的新客户资格以及预计2026-2028年将产生收入的后期管道增加。 It also highlighted new customer qualifications in Europe and Asia and late-stage pipeline additions expected to generate revenue in 2026–2028.